LUGANO, SWITZERLAND — June 19, 2002 —
Mega-CHOEP, a high-dose sequential CHOP regimen (cyclophosphamide, adriamycin, vincristine, and prednisone) plus etoposide, is a feasible primary treatment for aggressive non-Hodgkin’s lymphoma.
A phase II study indicates the therapy, which requires stem cell transplantation when completed, has a low toxicity profile and an encouraging survival rate. The study was carried out by researchers from hospitals in various German cities, on behalf of the German High-Grade Non-Hodgkin’s Lymphoma Study Group.
Dr. Bertham Glass, from University Hospital in Göttingen, Germany, presented the findings here Friday at the 8th International Conference on Malignant Lymphoma (ICML). From February 1997 to January 2002, the study enrolled 253 patients with newly diagnosed aggressive non-Hodgkin’s lymphoma. All patients, aged 18 to 60 years, had a high risk of relapse, defined by elevated lactate dehydrogenase (LDH) levels.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!